| Regular Group | Split-dose Group | Untreated Group | P (Regular vs. Untreated) | P (Split-dose vs. Untreated) | P (Regular vs. Split-dose) |
---|---|---|---|---|---|---|
Number of patients | 27 | 38 | 19 | Â | Â | Â |
Age in years, average ± SD | 61.0 ± 10.1 | 54.8 ± 14.9 | 62.8 ± 12.5 | NS | 0.049 | NS |
Gender (Male/Female) | 21/6 | 31/7 | 16/3 | NS | NS | NS |
Etiology | Â | Â | Â | Â | Â | Â |
   HBsAg (+) | 19 (70.4%) | 27 (71.1%) | 10 (52.6%) | NS | NS | NS |
   Anti-HCV (+) | 9 (33.3%) | 11 (28.9%) | 5 (26.3%) | NS | NS | NS |
   HBsAg (+)/anti-HCV (+) | 1 | 1 | 0 | - | - |  |
   HBsAg (-)/anti-HCV (-) | 0 | 1 | 4 | - | - |  |
Alcoholism | 11 (40.7%) | 21 (55.3%) | 7 (36.8%) | NS | NS | NS |
ECOG performance status | Â | Â | Â | NSa | NSa | NSa |
   0 | 9 | 19 | 7 |  |  |  |
   1 | 12 | 10 | 6 |  |  |  |
   2 | 6 | 9 | 6 |  |  |  |
Diagnosis | Â | Â | Â | - | - | - |
   Biopsy | 5 | 10 | 4 |  |  |  |
   Cytology | 9 | 9 | 0 |  |  |  |
   Imaging + alpha-fetoprotein | 13 | 19 | 15 |  |  |  |
Liver cirrhosis | 27 (100%) | 36 (94.7%) | 17 (89.5%) | NS | NS | NS |
Tumor size in cm, average ± SD | 6.62 ± 3.81 | 7.99 ± 4.55 | 8.71 ± 3.42 | NS | NS | NS |
Alpha-fetoprotein in ng/mL, median (range) | 448 (3-62208) | 2338 (3-248421) | 1491 (3 - 377218) | NS | NS | NS |
Portal vein thrombosis | 15 (55.6%) | 22 (59.5%) | 13 (68.4%) | NS | NS | NS |
Metastasis | 19 (70.4%) | 19 (50%) | 10 (52.6%) | NS | NS | NS |
   Lymph node | 10 | 10 | 4 |  |  |  |
   Lung | 8 | 10 | 7 |  |  |  |
   Bone | 1 | 2 | 1 |  |  |  |
   Duodenum | 1 | 0 | 0 |  |  |  |
   Adrenal gland | 1 | 0 | 0 |  |  |  |
   Kidney | 0 | 1 | 0 |  |  |  |
   Heart | 0 | 1 | 0 |  |  |  |
   Inferior vena cava | 0 | 1 | 0 |  |  |  |
Child-Pugh stage | Â | Â | Â | Â | Â | Â |
   A | 16 (59.3%) | 22 (57.9%) | 10 (52.6%) | NS | NS | NS |
   B | 11 | 16 | 9 |  |  |  |
Bilirubin in mg/dL, average ± SD | 1.44 ± 0.88 | 2.66 ± 5.20b | 2.86 ± 2.36c | 0.006 | NS | NS |
Previous therapy | 18 (66.7%) | 18 (47.4%) | No | - | - | NS |
   Percutaneous local ablation | 3 | 2 |  |  |  |  |
   TACE | 15 | 13 |  |  |  |  |
   Partial hepatectomy | 3 | 3 |  |  |  |  |
   Radiotherapy | 1 | 3 |  |  |  |  |
Course of FMP chemotherapy received | Â | Â | Â | Â | Â | Â |
   1 | 9 (33.3%) | 25 (65.8%) | 0 | - | - | 0.018 |
   2 | 11 | 9 | 0 |  |  |  |
   3 | 2 | 2 | 0 |  |  |  |
   >3 | 3 | 1 | 0 |  |  |  |